On the morning of June 5th, Jiangxi ChemPartner Research Co., Ltd. (hereinafter referred to as "Jiangxi ChemPartner") held its opening ceremony at the Gannan Innovation and Translational Medicine Research Institute. The event, themed "Smart Research for Life, Wisdom Gathering in Gannan," was attended by Li Hongliang, a member of the Standing Committee of the Party Committee and Vice President of Gannan Medical University, Lyu Haoyong, Deputy Secretary of the Party Committee of Zhanggong District in Ganzhou City, Wang Jingming, Director of the Management Committee of Zhanggong High-tech Zone, Zeng Xiaoying, Party Secretary of the Research Institute, Hu Ruilian, Chairman and CEO of ChemPartner, Fan Shixin, Special Assistant to the Chairman and General Manager of the Medical Strategic Cooperation Department of ChemPartner, as well as representatives from investment institutions and listed companies such as Hejun Capital, Qingfeng Pharmaceutical Group, Haipulos Group, and Rehabilitation Capital, along with deans, vice deans, and professors from several universities in Jiangxi Province, to witness the official launch of Jiangxi ChemPartner.

Jiangxi ChemPartner is a localized research and development service platform established by ChemPartner Technology Co., Ltd. (stock code: 300149.SZ, hereinafter referred to as "ChemPartner") to meet the domestic demand for innovative drug research and development services in Gannan. Jiangxi ChemPartner will rely on the platform and research service system of the listed company ChemPartner, combined with the industrial foundation of the Gannan region, as well as research platform resources such as the National Key Laboratory for New Drug Creation and the Model Animal Engineering Center of the Gannan Innovation and Translational Medicine Research Institute, to radiate the Guangdong-Hong Kong-Macao Greater Bay Area, further connecting the domestic and international needs for animal experiments, efficacy evaluation, and pharmacokinetics research in drug development, enhancing ChemPartner's customer reach, project undertaking, and localized service capabilities in the domestic market.

In recent years, the domestic innovative drug research and development has entered a new stage that emphasizes quality, efficiency, transformation, and global competitiveness. The demand for services such as preclinical research, efficacy evaluation, animal experiments, in vivo and in vitro evaluation, and translational medicine support continues to be released. ChemPartner's 2025 annual report shows that the company expects to achieve an operating income of 1.135 billion yuan in 2025, a year-on-year increase of 16.96%; among which, domestic income is expected to be 265 million yuan, a year-on-year increase of 61.01%, with the proportion of domestic income in total operating income rising from 16.96% in 2024 to 23.35%. The opening of Jiangxi ChemPartner is an important measure for the company to further get closer to domestic customers, improve the localized service network, and enhance regional project response capabilities.

It is reported that Jiangxi ChemPartner not only covers small animal in vivo and in vitro pharmacology and efficacy models but also has facilities for large animal experiments related to dogs, cats, monkeys, rabbits, and pigs. Relevant experimental services will be conducted within the scope of corresponding qualifications and compliance requirements. Jiangxi ChemPartner's core business focuses on pharmacology and efficacy evaluation and pharmacokinetics (PK) research, providing integrated experimental solutions for new drug development; in key areas such as cardiovascular and metabolic diseases, the platform can offer customized disease model services. Li Hongliang, Vice President of Gannan Medical University, introduced that this collaboration between the institute and enterprise represents a strong alliance between a national-level scientific innovation platform and a leading industrialization enterprise, complementing each other's advantages, and jointly opening up the entire innovation chain from AI intelligent screening—pharmacological validation—process development—industrialization landing, truly forming a virtuous industrial ecosystem where "source innovation is in the research institute, pilot transformation is in ChemPartner, and product landing is in Ganzhou." Jiangxi ChemPartner has landed in Ganzhou, which aligns with the direction of Jiangxi Province's support for the innovative development of the biopharmaceutical industry in recent years. The province has listed the pharmaceutical industry as a key focus in its "1269" action plan for cultivating and building industrial chains. On April 22, 2025, the National Major Innovation Platform Alliance, a biopharmaceutical innovation consortium led by the National Key Laboratory for New Drug Creation and gathering 13 national-level major innovation platforms, was launched in Ganzhou.

After the launch ceremony, attendees visited the site layout of Jiangxi ChemPartner and exchanged ideas on team building, platform capabilities, project services, and future development directions.

Hu Ruilian, Chairman and CEO of ChemPartner, stated that the company will take the opening of Jiangxi ChemPartner as an opportunity to further strengthen the synergy between the listed company platform and R&D service system and the innovative resources in the Ganzhou region, better serving domestic innovative drug companies, research institutions, medical device companies, and related industrial projects. This will provide new support for the company's domestic business expansion and customer service capabilities, jointly promoting the transformation of innovative results from the laboratory to clinical applications, from ideas to applications, and from Ganzhou to the nation and the world.

About ChemPartner

ChemPartner PharmaTech Co., Ltd., stock code 300149.SZ, is a life sciences R&D service company focused on preclinical CRO and CDMO. ChemPartner adheres to the mission of "empowering pharmaceutical innovation in all aspects, allowing life to meet hope sooner," and is committed to becoming a trusted partner for innovators in the global life sciences field. The company has established strategic partnerships with over 150 top global biopharmaceutical research institutions and companies, providing research services to more than 4,000 global pharmaceutical enterprises and biopharmaceutical technology companies, covering nearly all of the top 20 multinational pharmaceutical companies worldwide. As of 2025, the company has successfully assisted clients in advancing 17 new drugs from early R&D stages to global market sales